Anacor Pharmaceuticals, Inc.

UEI
HGNKDH1DLM86
CAGE
3AYC5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
pfizer.com
Founded
1849
Employees
50K-100K
Estimated annual revenue
$10B+
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Overcoming resistance by the application of boron to ribosomal inhibitors HDTRA114C0003 Defense Contract Management Agency $7,777,953

Grant awards

Award Agency Obligated Awarded
Novel oxaborole analogs for treatment of cutaneous leishmaniasis W81XWH1420171 Medical Command (Army) $473,020
Development of novel RHO kinase inhibitors for treatment of pulmonary hypertension W81XWH1420174 Department of Defense $519,575
Translation of novel PDE4 inhibitors for the treatment of acute spinal cord injury (SCI) W81XWH1110801 Department of Defense $148,361

Quick answers

Is Anacor Pharmaceuticals, Inc. registered in SAM.gov?

Anacor Pharmaceuticals, Inc.'s SAM.gov registration expired on February 26, 2020.

What is Anacor Pharmaceuticals, Inc.'s most recent federal award?

Anacor Pharmaceuticals, Inc.'s most recent federal grant award is Novel oxaborole analogs for treatment of cutaneous leishmaniasis (W81XWH1420171), from Medical Command (Army), on September 30, 2014.

On GovTribe

See Anacor Pharmaceuticals, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login